Drug Design, Development and Therapy (Sep 2020)

Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

  • Cabanillas Stanchi KM,
  • Willier S,
  • Vek J,
  • Schlegel P,
  • Queudeville M,
  • Rieflin N,
  • Klaus V,
  • Gansel M,
  • Rupprecht JV,
  • Flaadt T,
  • Binder V,
  • Feuchtinger T,
  • Lang P,
  • Handgretinger R,
  • Döring M

Journal volume & issue
Vol. Volume 14
pp. 3915 – 3927

Abstract

Read online

Karin Melanie Cabanillas Stanchi,1,* Semjon Willier,2,* Julia Vek,1 Patrick Schlegel,1 Manon Queudeville,1 Nora Rieflin,1 Veronika Klaus,1 Melanie Gansel,1 Joachim Vincent Rupprecht,1 Tim Flaadt,1 Vera Binder,2 Tobias Feuchtinger,2 Peter Lang,1 Rupert Handgretinger,1 Michaela Döring1 1Department of General Pediatrics, Hematology/Oncology, University Children‘s Hospital Tübingen, Tübingen, Germany; 2Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. Von Hauner Children’s Hospital, University Hospital, LMU, Munich, Germany*These authors contributed equally to this workCorrespondence: Michaela DöringDepartment I – General Pediatrics, Hematology/Oncology, University Hospital Tübingen - Children’s Hospital, Hoppe-Seyler-Str. 1, Tübingen 72076, GermanyTel +49-7071-2981355Fax +49-7071-295203Email [email protected]: High-dose myeloablative conditioning prior to autologous hematopoietic stem cell transplantation (autoHSCT) in pediatric patients is usually highly emetogenic. The antiemetic neurokinin-1 receptor antagonist fosaprepitant was safe and effective in children receiving highly emetogenic chemotherapy. Data on fosaprepitant during autoHSCT in children are currently not available.Methods: A total of 35 consecutive pediatric patients, who received an antiemetic prophylaxis with fosaprepitant (4 mg/kg; single dose, max. 1 x 150 mg/kg BW) and ondansetron (24-hours continuous infusion; 8– 32 mg/24h) or granisetron (2 x 40 μg/kg∙d− 1) during highly emetogenic conditioning chemotherapy before autoHSCT were retrospectively analyzed, and their results were compared with a control group comprising 35 consecutive pediatric patients, who received granisetron or ondansetron only. The antiemetic efficacy and the safety of the two prophylaxis regimens were compared with respect to three time periods after the first chemotherapy administration (0– 24h, > 24– 120h, > 120– 240h).Results: Clinical adverse events and clinically relevant increases/decreases of laboratory markers were similarly low and did not significantly differ between the two study groups (p> 0.05). The registered number of vomiting events was significantly higher in the control group in the time periods of 0– 24h (64 vs 22 events; p< 0.01), > 24– 120h (135 vs 78 events; p< 0.0001), > 120– 240h (268 vs 105 events; p< 0.0001), and the whole observation period 0– 240h (467 vs 205 events; p< 0.0001). The percentage of patients experiencing vomiting was higher in the control group during the time period of > 24– 120h (100% vs 74.3%) but not the other analyzed time periods (p> 0.05).Conclusion: The fosaprepitant-based antiemetic prophylaxis was safe, well tolerated and significantly reduced vomiting in children undergoing highly emetogenic chemotherapy prior to autoHSCT. Prospective randomized trials are necessary to confirm these results.Keywords: fosaprepitant, 5-HT3-antagonists, pediatric, antiemetic prophylaxis, chemotherapy-induced nausea and vomiting, autologous hematopoietic stem cell transplantation

Keywords